KLI

Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Neoadjuvant Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab

Metadata Downloads
Abstract
Purpose: The tumor-infiltrating lymphocytes (TILs) expression in breast cancer is a positive prognostic marker for certain breast cancer subtypes. We evaluated the efficacy of dual antihuman epidermal growth factor receptor 2 (HER2) blockade in HER2-positive breast cancer and hypothesized that high TILs tumors are associated with better outcomes.

Methods: A total of 176 patients who were treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) between December 2015 and December 2018 were reviewed. They were grouped based on a cut-off value of the stromal TILs grade (<= 20% TILs, > 20% TILs).

Results: In total, 107 patients (60.8%) achieved pathological complete response (pCR). Hormone receptor (HR)-negativity (p = 0.001) and a high TILs grade (p = 0.022) were independent predictors of pCR. Among the HR-negative patients, high TILs tumors were significantly associated with pCR (p = 0.035).

Conclusion: HR status and the TILs grade are significantly correlated with pCR in dual anti-HER2 neoadjuvant therapy. The evaluation of the TILs at baseline may be beneficial for predicting pCR in HER2-positive breast cancer.
Author(s)
고범석공경엽김성배김정은김학희안진희이희진정경해정일용정재호채은영하주영
Issued Date
2021
Type
Article
Keyword
ReceptorErbB-2Neoadjuvant therapyLymphocytesTumor microenvironment
DOI
10.4048/jbc.2021.24.e36
URI
https://oak.ulsan.ac.kr/handle/2021.oak/8143
https://ulsan-primo.hosted.exlibrisgroup.com/primo-explore/fulldisplay?docid=TN_cdi_nrf_kci_oai_kci_go_kr_ARTI_9856025&amp;context=PC&amp;vid=ULSAN&amp;lang=ko_KR&amp;search_scope=default_scope&amp;adaptor=primo_central_multiple_fe&amp;tab=default_tab&amp;query=any,contains,Tumor-Infiltrating%20Lymphocytes%20in%20Human%20Epidermal%20Growth%20Factor%20Receptor%202-Positive%20Breast%20Cancer%20Receiving%20Neoadjuvant%20Docetaxel,%20Carboplatin,%20Trastuzumab,%20and%20Pertuzumab&amp;offset=0&amp;pcAvailability=true
Publisher
JOURNAL OF BREAST CANCER
Location
대한민국
Language
영어
ISSN
1738-6756
Citation Volume
24
Citation Number
4
Citation Start Page
359
Citation End Page
366
Appears in Collections:
Medicine > Medicine
공개 및 라이선스
  • 공개 구분공개
파일 목록
  • 관련 파일이 존재하지 않습니다.

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.